LG Chem LUCON® TX5007, the Engineering Plastic Used for Electrostatic Powder Coating Is Now Applied to Japanese Global OEM’s Front Fenders
LG Chem (KRX: 051910) has started supplying engineering plastics to Mitsubishi Motors for its powder coating parts used as the front fenders of RVR, Delica D:5 and Outlander models.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230103005882/en/
RVR (Photo: Business Wire)
Front fender is located on the side of the vehicles, which not only acts as one of key factors in the exterior design but also protects its wheels from road debris. Thus, it not only should possess a high level of mechanical robustness but also an excellent exterior quality to keep a high integrity design with the rest of the car body.
LUCON TX5007 developed by LG Chem is a compound material that combines modified polyphenylene ether (mPPE) and polyamide (PA66) alloy with carbon nanotubes (CNTs), and has an excellent electrical conductivity and show strong mechanical properties. In addition, this product has an outstanding heat resistance, making it suitable for the automotive on-the-line painting process at 200 °C or higher. At the same time, it also provides an excellent dimensional stability thanks to its low coefficient of linear thermal expansion (CLTE).
In general, applying plastics instead of steel/aluminum contributes to automotive light weight. When a plastic fender is used, the weight of the vehicle is reduced by about 4 kg, which also improves fuel efficiency. Furthermore, plastic fenders can provide other benefits, such as reduced fuel exhaust emissions and carbon footprints.
In addition to LUCON TX5007, LG Chem has a broad portfolio of products that can be used for large-scale automotive exterior parts that need to utilize powder coating process. These products can be customized to meet automotive suppliers’ diverse parts requirements for fenders, bumper panels, hoods, tailgates, fuel doors, and side mirrors.
At the same time, LG Chem is using CNT, a filler that produces excellent conductivity even with a small amount in its engineering plastics to support diverse requirements of customers. Since this material can cover a wider range of electrical conductivity compared to other carbon fillers such as Carbon Black and Carbon Fiber, it is considered an optimal solution for powder coating. LG Chem has not only built its own CNT production line, but now expanding its 4th plant for a mass production in 2024, for the reliable supply of high-quality products for powder coating.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005882/en/
Contact information
LG Chem, Ltd.
Sangkuhn Sung, Manager
+82-2-3773-5136
sungsk@lgchem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Adds González-Paullada Domínguez in Monterrey, Mexico7.1.2026 16:30:00 EET | Press release
Andersen Global broadens its Latin American platform through a Collaboration Agreement with Monterrey-based law firm González-Paullada Domínguez (GPD), further strengthening the organization’s coverage in Mexico. Founded in 2021, GPD offers comprehensive services across transactional and litigation matters. The firm advises clients across sectors—including manufacturing, real estate, insurance, information technology, mining, and banking—on corporate law, mergers and acquisitions, real estate transactions, foreign investment, commercial contracts, regulatory compliance, and ongoing legal audits. GPD also represents clients in complex civil and commercial litigation, arbitration, and insolvency proceedings. “Monterrey is a major economic hub where local credibility and deep relationships are essential, particularly for foreign investors seeking to enter the market,” said Alfonso González-Paullada Guerrero, founder and managing partner of GPD. “By collaborating with Andersen Global, we s
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 15:15:00 EET | Press release
1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new intelligent data program called 1NCE Insights. The program is part of the company’s goal of fusing AI + IoT intelligence to drive game-changing results in supply chains, smart cities, utilities and beyond. Customer-collected data is theirs and theirs alone. But with Insights, 1NCE opens access to its anonymized, networkwide data. Customers can benchmark their IoT projects a
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 15:00:00 EET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
